ABAgnes Boltz

Agnes Boltz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Agnes Boltz has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Inter-Formula Variability in IOL Power Planning in Short and Long Eyes: A Retrospective Paired Comparison of Seven ESCRS-Hosted Formulas and the Ladas Super Formula 2.0

    by Michal Klimek, Andreas Földesi, Dejan Botic, Valerie Golsch, Rafah Khandour, Maximilian Tamberger, Agnes Boltz, Pia Veronika Vécsei-Marlovits

    Purpose: To quantify the frequency, magnitude, and direction of inter-formula planning variability in intraocular lens (IOL) power calculation at the extremes of axial length, comparing seven European Society of Cataract and Refractive Surgeons (ESCRS)-hosted formulas and the Ladas Super Formula 2.0, and to identify preoperative predictors of clinically relevant disagreement. Methods: In this retrospective, single-center, paired within-eye planning study, the recommended IOL power and predicted spherical equivalent were generated for short (axial length 22 mm) and long (> 26 mm) eyes from identical biometry (IOLMaster 700) across the seven formulas on three IOL platforms. A clinically relevant discrepancy (ClinRel) was defined as a within-eye range ≥ 1 step (≥ 0.5 D) in recommended power or ≥ 0.25 D in predicted spherical equivalent across the seven formulas. Firth-penalized logistic regression identified predictors in the long stratum. Results: A total of 1020 eyes (551 short, 469 long) of 665 patients were analyzed. On the primary platform, ClinRel occurred in 98.2% of short and 62.7% of long eyes, reproduced on all three platforms and in one-eye-per-patient analyses. Per-formula mean signed differences vs Barrett Universal II were small (− 0.11 to +0.16 D), yet the seven formulas diverged by ≥ 2 steps in 33.8% of short eyes. Hill-RBF 3.0 was out-of-bounds in ~30% of eyes; the Ladas Super Formula 2.0 (n = 311) was not a directional outlier. In long eyes, axial length was the strongest predictor (Firth odds ratio 1.55 per 1 SD; 95% CI 1.23– 1.95), with no clean threshold (Youden axial length/corneal radius ratio 3.52; sensitivity 35.5%, specificity 96.0%). Conclusions: Modern IOL power formulas frequently disagree on the recommended power in short and long eyes despite comparable published accuracy. Because postoperative outcomes were not assessed, these findings quantify planning-level variability only; disagreement should alert surgeons to planning uncertainty in these eyes.

  • Open Access

    Comparison of morphological and functional parameters after switching therapy from brolucizumab to faricimab in neovascular age-related macular degeneration

    by Agnes Boltz, Jasmin Paster, Sarah Mehany, Veronika Pia Vécsei-Marlovits

    Background: Brolucizumab, an anti-vascular endothelial growth factor (VEGF) agent, offers extended dosing intervals in neovascular age-related macular degeneration (nAMD) but carries a rare risk of retinal vasculitis. Faricimab, a bispecific antibody targeting VEGF and angiopoietin-2 (Ang-2), maintained efficacy with dosing intervals of up to 16 weeks in the TENAYA and LUCERNE trials and carries a lower reported inflammatory risk. Patients may therefore be switched from brolucizumab to faricimab. This study examines the morphological and functional response after such a switch. Methods: Patients with nAMD were included in this retrospective case series. Eligibility required at least three consecutive brolucizumab injections before switching to faricimab. The primary outcome was the change in central retinal thickness (CRT); secondary outcomes were the change in best-corrected visual acuity (VA) and adverse events. Results: The study included 31 eyes from 28 patients treated with brolucizumab and switched to faricimab. Mean visual acuity (VA) was 0.3 logMAR (Snellen equivalent ~20/40) at visit -3, with no significant change after three brolucizumab injections (0.3 logMAR, ~20/40, p=0.932). After switching to faricimab, mean VA was 0.332 logMAR (~20/40) with no statistically significant difference from the value after three brolucizumab injections (p=0.187). Central retinal thickness (CRT) remained stable before (355.00µm to 347.29µm, p=0.538) and after switching (366.54µm, p=0.190). Of the 11 eyes that were free of fluid before the switch, 10 did not remain dry, and CRT increased significantly (282.9µm to 367.9µm, p=0.013) after extending intervals on average by +2.3 weeks (min 0 to max +5 weeks). However, visual function remained stable (p=0.559). In contrast, two eyes became dry with shorter intervals (-2 weeks), one eye remained dry (+2 weeks) and 18 eyes remained active (-0.5 weeks). Conclusions: Overall, morphological and functional parameters remained stable after switching to faricimab, and the safety profile was stable. Because every eye received both agents sequentially and no concurrent brolucizumab control group was included, this was not a head-to-head comparison. The increase in retinal thickness in some cases highlights the need for individualized treatment based on patient response.

  • Open Access

    Effect of intravitreal injections due to neovascular age-related macular degeneration on retinal nerve fiber layer thickness and minimum rim width: a cross sectional study

    by Agnes Boltz, Tanja Spöttl, Wolfgang Huf, Birgit Weingessel, Veronika Pia Vécsei-Marlovits

    Purpose: The present study tested the hypothesis that repeated anti-VEGF injections are associated with reduced retinal nerve fiber layer (RNFL) and minimum rim width (MRW) of the optic nerve head. Patients and methods: Sixty-six patients with a history of intravitreal injections due to neovascular age-related macular degeneration were included. RNFL and MRW were measured using optical coherence tomography (Spectralis OCT, Heidelberg Engineering, Heidelberg, Germany). Results: Mean global RNFL was 90.62 μm and both RNFL as well as MRW significantly decreased with advanced age (p = 0.005 and p = 0.019, respectively). Correlating for the number of injections, no significant impact on RNFL was found globally (p = 0.642) or in any of the sectors. In contrast, however, global MRW was significantly reduced with increasing numbers of intravitreal injections (p = 0.012). The same holds true when adjusted for the confounding factor age (RNFL p = 0.566 and MRW p = 0.023). Conclusion: Our study shows that repeated intravitreal injections due to choroidal neovascularization seem to have a deleterious effect on MRW but not on RNFL. This suggests that MRW is a more sensitive marker than RNFL for evaluating the effect of frequent intravitreal injections on the optic nerve head since it seems to be the first structure affected.


  • Brolucizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to aflibercept and bevacizumab

    by Agnes Boltz, Katharina Radunsky, Birgit Weingessel, Veronika Pia Vécsei-Marlovits

    Purpose Treatment of choroidal neovascularization due to age-related macular degeneration is a challenging topic since an increasing number of patients show reduced morphological response to conventional treatment with intravitreal injections. The present study tested the hypothesis that the newly introduced anti-VEGF antibody brolucizumab does not only show promising results in pre-treated patients but is also a viable option in cases of tachyphylaxis to aflibercept or bevacizumab. Methods Thirty-six eyes of 34 patients with a history of at least 10 anti-VEGF injections as well as persistent retinal fluid following the past 5 monthly injections with aflibercept and bevacizumab prior to first treatment with brolucizumab were included in the study. Morphological and functional treatment response was compared before and after switching to brolucizumab. Results Mean best-corrected visual acuity did not significantly change after treatment with brolucizumab. In contrast, central retinal thickness significantly decreased 4 weeks after treatment with brolucizumab from 340.36 to 282.22 µm (p < 0.001) as well as pigment epithelial detachment from 346.73 to 280.47 µm (p < 0.001). In 24 eyes (66.67%), complete resolution of intra-and subretinal fluid was observed after a single dose of brolucizumab. No serious adverse events, such as intraocular inflammation and retinal vasculitis, were reported after a single injection of brolucizumab. Conclusion Brolucizumab is not only effective in treatment-naïve patients as shown in the pivotal HAWK and Harrier trials, but also in pre-treated patients as seen in the present study. Our data also suggest that brolucizumab is potent in patients with signs of tachyphylaxis to other anti-VEGF agents and thus a viable treatment option.